FreeTrials & Tribulations Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization” January 27, 2023Vol.49 No.04By Mark J. Ratain and Garth W. Strohbehn
Conversation with The Cancer Letter City of Hope’s Mustafa Raoof: Medicare Advantage cancer patients more likely to die within 30 days after complex surgery January 20, 2023Vol.49 No.03By Matthew Bin Han Ong
Trials & Tribulations Pancreatic cancer survival edges up—as screening strategies emerge January 20, 2023Vol.49 No.03By Rosario Ligresti
Moderna’s mRNA cancer vaccine improves survival in phase IIb melanoma study—first observation of efficacy in an RCT December 16, 2022Vol.48 No.45By Matthew Bin Han Ong
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
A brief report sets forth a “new normal,” lets NCI start to streamline clinical trials November 11, 2022Vol.48 No.41By Paul Goldberg
Trials & Tribulations All colorectal cancer patients require germline testing at diagnosis and somatic testing at advanced disease diagnosis July 15, 2022Vol.48 No.28By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Trials & Tribulations Burnout from the elusive quest for quality July 15, 2022Vol.48 No.28By Banu E. Symington
Trials & Tribulations Transforming the future of radiation oncology:Three ways collaboration accelerates FLASH radiation therapy research June 24, 2022Vol.48 No.25By Karen J. Kirkby
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
